Spondyloarthritis & psoriatic arthritis

Remote monitoring or patient-initiated care in axial spondyloarthritis: a 3-armed randomised controlled noninferiority trial

Ann Rheum DisPublished Randomised controlled trial

Authors' conclusion

In patients with axSpA in low disease activity and on stable treatment with tumour necrosis factor inhibitor, follow-up with remote monitoring or patient-initiated care was noninferior to usual care in maintaining low disease activity

Study context

Population
Patients with axial spondyloarthritis (axSpA) in low disease activity on stable TNFi treatment, Norwegian outpatient clinic235 completed
Participants
243 patients
Comparison
Remote monitoring vs patient-initiated care vs usual care
  • Remote monitoringn = 75
  • Patient-initiated caren = 79
  • Usual caren = 81reference
Primary endpoint
Mean probability of ASDAS <2.1, compared between groups at 6, 12 and 18 months; 15% noninferiority margin
Follow-up
6, 12 and 18 months
Methodological details3-armed, parallel-group, open-label, noninferiority
  • 3-armed
  • Parallel-group
  • Open-label
  • Noninferiority

Primary result

As reported in the abstract

Probability of ASDAS <2.1
Estimated difference of probability, %
Usual carevs Remote monitoring
−4.1(97.5% CI −9.9% to 1.8%)
Usual carevs Patient-initiated care
−1.1(97.5% CI −7.2% to 4.9%)
Remote monitoringvs Patient-initiated care
2.9(95% CI −1.5% to 7.4%)

Non-inferiority margin 15 as printed, not drawn

Secondary outcomes

Health providers' resource use

Lowest in patient-initiated care

Other secondary outcomes

Comparable

Original publication

Remote monitoring or patient-initiated care in axial spondyloarthritis: a 3-armed randomised controlled noninferiority trial. Ann Rheum Dis. Published 23 May 2025. doi:10.1016/j.ard.2025.04.019

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.